463 related articles for article (PubMed ID: 19075129)
1. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
3. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
4. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
7. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
8. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
9. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
11. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
12. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
[TBL] [Abstract][Full Text] [Related]
14. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
15. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
Lee KA; Cho KJ; Kim SH; Shim JH; Lim JS; Cho DH; Song MS; Dinarello CA; Yoon DY
Cancer Lett; 2005 Nov; 229(2):261-70. PubMed ID: 16125299
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
17. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
[TBL] [Abstract][Full Text] [Related]
18. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
19. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
Routes JM; Ryan S; Li H; Steinke J; Cook JL
Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035
[TBL] [Abstract][Full Text] [Related]
20. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
